关节炎治疗与卵巢储备关联的前瞻性研究
该前瞻性队列研究纳入129例绝经前关节炎女性,在T0和T1两个时间点测AMH,并与198例无关节炎女性血清样本库对比。关节炎女性年龄校正后AMH中位数显著低于无关节炎者(2.21 ng/ml vs 2.78 ng/ml,P=0.009)。甲氨蝶呤单用或联合TNF-α拮抗剂者年度AMH下降幅度处于最高四分位的可能性更低。
要点
- 关节炎女性年龄校正后AMH显著低于无关节炎对照。
- 甲氨蝶呤长期使用与年度AMH下降无关联。
- 年龄超过35岁或有不孕就诊史者AMH年降幅更大。
核心结论
- 关节炎女性AMH低于健康对照,但长期甲氨蝶呤使用与年度AMH下降无关联。
研究设计与样本
- 前瞻性队列研究,129例绝经前关节炎女性在T0和T1测AMH,与198例无关节炎女性血清样本库对比。
- T0与T1中位间隔1.72年。
主要发现
- T0时关节炎女性年龄校正AMH中位数显著低于无关节炎女性(2.21 ng/ml vs 2.78 ng/ml,P=0.009)。
- DOR(AMH<1.1 ng/ml)最高风险者为有输卵管绝育史或年龄超过35岁的关节炎女性。
- 年度AMH下降超过75百分位(年降幅超过28%)最高比值者为年龄超过35岁或因不孕就诊者。
- 单用甲氨蝶呤(OR 0.08,95%CI 0.01-0.67)或甲氨蝶呤联合TNF-α拮抗剂(OR 0.13,95%CI 0.02-0.89)者年度AMH下降处于最高四分位的可能性低于未用药者。
关键数值与推荐
- DOR定义为AMH<1.1 ng/ml。
- 年度AMH下降超过75百分位对应年降幅超过28%。
临床怎么用
- 对关节炎绝经前女性应关注卵巢储备,尤其年龄超过35岁、有输卵管绝育史或不孕就诊史者。
- 甲氨蝶呤长期使用未显示与年度AMH下降相关,用药决策可参考此安全性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RESEARCH QUESTION: How do anti-Müllerian hormone (AMH) concentrations in women with and without arthritis compare? Is there an association between AMH and arthritis drug regimen? DESIGN: In this prospective cohort study, AMH was measured at two time points (T0 and T1) in 129 premenopausal women with arthritis. AMH at T0 was compared with that from a bank of serum samples from 198 premenopausal women without arthritis. Primary outcomes were: (i) diminished ovarian reserve (DOR) (AMH <1.1 ng/ml) and (ii) annual rate of AMH decrease. Univariate, multivariable and Firth logistic regression identified variables associated with annual AMH decrease in excess of the 75th percentile. RESULTS: Median time between T0 and T1 was 1.72 years. At time T0, median age-adjusted AMH in women with arthritis was significantly lower than that of women without arthritis (median 2.21 ng/ml versus 2.78 ng/ml; P = 0.009). Women with arthritis at highest risk for DOR had a history of tubal sterilization or were over the age of 35. Those with highest odds of having an annual AMH decrease in excess of the 75th percentile (over 28% decrease per year) were those: over the age of 35 or who sought care for infertility. Women with arthritis taking methotrexate alone (OR 0.08, 95% CI 0.01-0.67) or methotrexate plus tumour necrosis factor-alpha antagonists (OR 0.13, 95% CI 0.02-0.89) were less likely to be in the highest quartile of annual AMH decrease than women with arthritis not taking medication. CONCLUSIONS: Women with arthritis had lower AMH than healthy controls. Long-term methotrexate use was not associated with an annual AMH decrease.
引用
- Alexander VM, Ashley-Martin J, Riley JK, et al. Association between arthritis treatments and ovarian reserve: a prospective study. Reprod Biomed Online. 2021. PMID: 33931373. doi:10.1016/j.rbmo.2021.03.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。